Drug Details
General Information of the Drug (ID: DR4377) | ||||
---|---|---|---|---|
Name |
Rasagiline
|
|||
Synonyms |
rasagiline; 136236-51-6; (R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine; Azilect; (R)-N-2-Propynyl-1-indanamine; (R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine; 1-Indanamine, N-2-propynyl-, (R)-; (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; UNII-003N66TS6T; TV-1030; Azilect (TN); RAS; CHEMBL887; (1R)-N-propargylindan-1-amine; CHEBI:63620; 003N66TS6T; (R)-Indan-1-yl-prop-2-ynyl-amine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)-; (R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; Rasagiline [USAN:INN]; MFCD00866571; HSDB 7699; (1R)-N-prop-2-ynylindan-1-amine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R); TV 1030; PubChem23269; Rasagiline (USAN/INN); SCHEMBL74699; cc-221; MLS006012042; N-propargyl-1-(R)aminoindan; GTPL6641; IND057; SCHEMBL2029054; DTXSID3041112; BDBM10989; HMS3264K12; HMS3715L12; HMS3886N03; Pharmakon1600-01502333; AC-723; ANW-49399; HY-14605A; NSC759639; NSC789038; s5795; ZINC19875504; AKOS006271452; AKOS015837675; AM84542; CCG-213034; DB01367; FS-3130; MCULE-4385913742; NSC 759639; NSC-759639; NSC-789038; SMR002533187; (1R)-N-(prop-2-yn-1-yl)indan-1-amine; AB0035569; DB-001111; A2916; X9941; D08469; S-3541; AB01562963_01; AB01562963_02; Q420685; SR-00000006359; SR-00000006359-3; 1204184-69-9
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Parkinson's disease [ICD-11: 8A00] | Approved | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C12H13N
|
|||
PubChem CID | ||||
Canonical SMILES |
C#CCNC1CCC2=CC=CC=C12
|
|||
InChI |
1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
|
|||
InChIKey |
RUOKEQAAGRXIBM-GFCCVEGCSA-N
|
|||
CAS Number |
CAS 136236-51-6
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Idebenone | Diplocentrus melici | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | DICER1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | Lin-28A | Molecule Info | |||
Up-regulation | Expression | LIN28B | Molecule Info | |||
Down-regulation | Expression | microRNA let-7a-3 | Molecule Info |
Pathway MAP
|
||
Experimental
Result(s) |
Combination therapy with rasagiline and idebenone produced a synergistic effect that ameliorated RIR injury, restored visual function and provided neuroprotection. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Monoamine oxidase B (MAO-B) | Molecule Info | [3] | |
BioCyc | Superpathway of tryptophan utilization | Click to Show/Hide | ||
2 | Tryptophan degradation via tryptamine | |||
3 | Dopamine degradation | |||
4 | Putrescine degradation III | |||
5 | Noradrenaline and adrenaline degradation | |||
KEGG Pathway | Glycine, serine and threonine metabolism | Click to Show/Hide | ||
2 | Arginine and proline metabolism | |||
3 | Histidine metabolism | |||
4 | Tyrosine metabolism | |||
5 | Phenylalanine metabolism | |||
6 | Tryptophan metabolism | |||
7 | Drug metabolism - cytochrome P450 | |||
8 | Metabolic pathways | |||
9 | Serotonergic synapse | |||
10 | Dopaminergic synapse | |||
11 | Cocaine addiction | |||
12 | Amphetamine addiction | |||
13 | Alcoholism | |||
Panther Pathway | Adrenaline and noradrenaline biosynthesis | Click to Show/Hide | ||
2 | 5-Hydroxytryptamine degredation | |||
3 | Dopamine receptor mediated signaling pathway | |||
Pathway Interaction Database | Alpha-synuclein signaling | Click to Show/Hide | ||
WikiPathways | Tryptophan metabolism | Click to Show/Hide | ||
2 | Dopamine metabolism | |||
3 | Phase 1 - Functionalization of compounds |



